As filed with the Securities and Exchange Commission on January 6, 2026. Registration Statement No. 333-292131 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________ Invea Therapeutics, Inc. (Exact name of registrant as specified in its charter) __________________________________ Delaware 2834 87-3198325 (State or other jurisdiction of inc ...

Core Insights - KBR, Inc. has enhanced its presence in the U.S. by securing a Technical Support Services Contract from the U.S. Geological Survey, leading to a 6.7% increase in its stock price [1] Group 1: Contract Details - KBR has obtained a single Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to $350 million to support USGS in Earth observation initiatives, including the upcoming Landsat Next satellite constellation set for launch in 2030 [2] - The contract involves modernizing USGS operations through cloud-native systems, AI, machine learning, and enterprise-scale IT solutions, focusing on data analytics and secure IT infrastructure [3] Group 2: Company Capabilities and Partnerships - KBR leverages over 24 years of experience in advanced engineering and data analytics, reinforcing its role as a trusted partner for USGS in environmental intelligence and planetary stewardship [4] - The company’s backlog has shown strong growth, reaching $23.35 billion at the end of Q3 FY25, a 5.6% increase year-over-year, supported by favorable market conditions and U.S. government emphasis on national security and sustainability [5][6] Group 3: Stock Performance and Market Context - KBR's stock has experienced a slight decline of 0.7% over the past month, contrasting with a 3.4% decline in the Zacks Engineering - R and D Services industry, influenced by factors such as the U.S. government shutdown affecting new awards [7]

Core Viewpoint - ScanTech AI Systems Inc. is currently undergoing a Nasdaq listing compliance process and is engaged in restructuring discussions with creditors, with a hearing scheduled for January 22, 2026 [2][5]. Group 1: Nasdaq Listing Compliance - The Company has requested a hearing before the Nasdaq Hearings Panel due to compliance issues identified by Nasdaq's Listing Qualifications Department [2]. - The Company's securities remain listed on Nasdaq pending the outcome of the hearings process [2]. - A 1-for-20 reverse stock split was implemented, effective December 16, 2025, as part of corrective actions taken by the Company [3]. Group 2: Restructuring and Creditor Management - The Company is evaluating its capital structure and liquidity position while engaging in discussions with creditors regarding potential restructuring or resolution of outstanding obligations [4]. - Ongoing discussions with creditors may involve disputes over certain asserted defaults or amounts, with no definitive agreements reached yet [4]. - The Company is working with advisors to address both listing compliance and broader restructuring considerations in an orderly manner [5]. Group 3: Company Overview - ScanTech AI Systems Inc. has developed advanced non-intrusive 'fixed-gantry' CT screening technologies that utilize proprietary AI and machine learning to detect hazardous materials [6]. - The Company's solutions are designed for high-security environments such as airports, seaports, borders, and government buildings [6].

Core Insights - Recursion, a clinical stage TechBio company, focuses on decoding biology to significantly enhance lives [1] - The CEO, Najat Khan, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - The company will also participate in the 28th Annual Needham Growth Conference on January 16, 2026 [1] Company Overview - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [2] - The company has additional offices in Montréal, New York, London, and the Oxford area [2] - Recursion utilizes a platform called Recursion OS, which generates one of the largest proprietary biological and chemical datasets globally [1] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [1] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world to advance medical research [1]

Core Insights - The company's bfLEAP® platform has demonstrated a significant increase in mean survival rates for pancreatic cancer patients, showing an almost threefold improvement from control to treatment arms [1][3][4] - Data from the pancreatic cancer trial will be presented at the 2026 ASCO GI symposium and subsequently published in the Journal of Clinical Oncology [2] Company Overview - BullFrog AI Holdings, Inc. utilizes artificial intelligence and machine learning to transform complex biomedical data into actionable insights, aiming to enhance drug discovery and development [6] - The company collaborates with leading research institutions to apply causal AI and its proprietary platforms, bfLEAP® and bfPREP™, to analyze complex clinical datasets [6] Research Findings - The study focused on glufosfamide, an investigational chemotherapeutic agent, and identified key biomarkers that contributed to the increased survival rates in pancreatic cancer patients [3][4] - The research concluded that data-driven clustering approaches can effectively refine patient stratification and guide personalized treatment strategies [4]

Core Insights - The market is showing signs of potential growth, with the S&P 500 gaining over 16% and the Nasdaq 100 climbing about 20% in the past year, indicating confidence in growth stocks [1] - Long-term investment strategies are emphasized, with companies like Lemonade and Pagaya Technologies identified as high-growth stocks that could see significant appreciation by 2036 [2] Company: Lemonade - Lemonade is a digital insurance company that has rapidly grown since its inception over a decade ago, appealing particularly to younger customers through its online platform [4] - The company differentiates itself from traditional insurance models by utilizing a seamless digital system that enhances pricing and claims management, leveraging extensive data and machine learning [5] - Lemonade's market capitalization is $5.7 billion, with a current stock price of $76.94 and a year-over-year increase of 30% in in-force premium as of the third quarter [7] - The company is approaching net profitability, expecting to break even next year, which could lead to a tenfold increase in stock value over the next decade [8] Company: Pagaya - Pagaya operates a credit evaluation and lending platform that facilitates lower-risk approvals for creditors and higher approval rates for borrowers, selling approved loans as asset-backed securities [9] - The company has established partnerships with 31 lending partners, including notable names like Visa and SoFi Technologies, and has 154 funding partners for its ABS deals [10] - Pagaya's market capitalization is $2.0 billion, with a current stock price of $24.26 and a year-over-year revenue increase of 36% in the third quarter, alongside a net income of $23 million [11][12] - The company is positioned to thrive in various interest rate environments, with a valuation that allows for significant growth potential, similar to Lemonade [14]

Core Insights - One Stop Systems, Inc. (OSS) is focused on rugged enterprise-class computing, particularly in artificial intelligence (AI), machine learning (ML), and edge sensor processing [1][5] - Industrial Alliance Securities has set a price target of $9 for OSS, indicating a potential price increase of approximately 25.75% from its current price of $7.16 [1][5] Financial Performance - OSS has sold Bressner Technology GmbH to Hiper Euro GMBH for $22.4 million, allowing the company to concentrate on its core markets [2][5] - The original acquisition cost of Bressner was $5.6 million in 2018, resulting in a significant return on investment [2] - OSS's current stock price is $7.01, reflecting a 3.01% increase, with fluctuations between $6.69 and $7.41 during the trading day [3] - Over the past year, OSS's stock has experienced a high of $7.92 and a low of $1.85, indicating significant volatility [3][5] Market Activity - OSS's market capitalization is approximately $150.88 million, with a trading volume of 522,439 shares on the NASDAQ exchange [4]

Company Overview - Applied Digital Corporation operates in the technology infrastructure market, focusing on digital infrastructure for high-demand computing applications, particularly supporting AI and HPC workloads through specialized data centers and cloud services [5] - The company generates revenue through infrastructure services for crypto mining, GPU computing solutions, and the design, construction, and management of data centers, serving enterprise clients in AI, machine learning, and HPC sectors across North America [6] Financial Performance - As of September 30, Applied Digital reported a revenue of $64.2 million for the fiscal third quarter, reflecting an 84.3% year-over-year increase [10] - The company has a market capitalization of $6.34 billion and a total revenue of $219.02 million for the trailing twelve months (TTM), with a net loss of $225.71 million [4] Stock Performance - As of November 13, shares of Applied Digital were priced at $23.06, which is a 221.6% increase over the past year [3] - The stock has gained 231.4% over the last year, significantly outperforming the S&P 500 index's 17.7% return and the Nasdaq Composite's 20% [9] Investment Activity - Hood River Capital Management LLC sold 812,377 shares of Applied Digital during the third quarter, reducing its position by 3.7%, while the remaining stake stands at 21,046,654 shares valued at $482.8 million, representing 5.7% of the fund's assets under management [2][3][9]

Group 1 - Zealand Pharma will participate in the 44th J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California [1] - Adam Steensberg, President and CEO, will present and engage in a fireside chat on January 14 at 1:30 PM PST / 10:30 PM CET, with a live audio webcast available [2] - The company focuses on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and a proprietary data platform utilizing advanced data-driven and AI/ML approaches [3] Group 2 - More than ten drug candidates invented by Zealand Pharma have entered clinical development, with two products already on the market and three candidates in late-stage development [4] - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts [4]

Core Viewpoint - The Zacks Consumer Loans industry is experiencing a positive outlook due to falling interest rates and easing lending standards, which are expected to sustain and boost loan demand, thereby supporting top-line growth [1][2]. Industry Overview - The Zacks Consumer Loans industry includes companies that provide various loan products such as mortgages, credit card loans, and personal loans, generating net interest income (NII) as a primary revenue source. The industry's prospects are closely tied to the overall economic condition and consumer sentiment [3]. - Companies in this sector also engage in commercial lending, insurance, loan servicing, and asset recovery, which help diversify revenue sources and reduce dependence on economic fluctuations [3]. Key Themes Interest Rates & Loan Demand - The Federal Reserve has reduced interest rates by 175 basis points since 2024, with indications of another cut. Despite a decline in consumer confidence due to job and income concerns, loan demand is expected to remain stable or improve as rates decrease, leading to modest growth in net interest margin (NIM) and NII [4]. Lending Standards - The removal of tax liens from consumer credit reports has improved credit scores, expanding the borrower base. Easing lending standards are enabling consumer loan providers to meet the rising loan demand [5]. Asset Quality - Lower interest rates are likely to enhance borrowers' repayment capabilities, reducing the need for consumer loan providers to set aside large reserves for potential defaults. However, a slight increase in non-performing loans is anticipated, which may impact asset quality [6]. Industry Performance - The Zacks Consumer Loans industry has outperformed the Zacks S&P 500 composite and the finance sector over the past two years, with a collective stock increase of 101.7%, compared to 49.2% for the S&P 500 and 42% for the finance sector [11]. Valuation Metrics - The industry has a trailing 12-month price-to-tangible book ratio (P/TBV) of 1.42X, above the five-year median of 1.04X. This ratio indicates that the industry is trading at a significant discount compared to the broader market, where the S&P 500's P/TBV is 12.86X [14][16]. Investment Opportunities Enova International, Inc. (ENVA) - Enova is a financial technology company focused on online financial services, with a market cap of $4.01 billion. The company has seen a 63.7% increase in shares over the past year, and earnings are expected to grow by 39.5% in 2025 [19][22]. Encore Capital Group, Inc. (ECPG) - Encore Capital specializes in debt recovery and has a market cap of $1.3 billion. The company has gained 17% in share value over the past year, with earnings projected to increase by 93.5% in 2025 [24][27].